Lyra therapeutics announces positive topline results from beacon phase 2 study of lyr-220 for the treatment of chronic rhinosinusitis (crs) in patients with prior ethmoid sinus surgery

Study demonstrates statistically significant and clinically relevant improvements in 3 cardinal symptoms and snot-22 scores at 24 weeks
LYRA Ratings Summary
LYRA Quant Ranking